Samidorphan is an opioid antagonist that in the form of olanzapine/samidorphan is used in the treatment of schizophrenia and bipolar disorder. Samidorphan reduces the weight gain associated with olanzapine. Samidorphan is taken by mouth. Technically, samidorphan is a small molecule mu opioid receptor antagonist with activity at other opioid receptor subtypes at lower affinity. It is formulated as an oral tablet in fixed-dose combination with olanzapine for clinical use. Pharmacologically, blockade of mu opioid receptors is believed to underlie its effects on reward and appetite pathways. Key development and product characteristics include a defined chemical entity with a single major stereochemical configuration, reproducible oral absorption, metabolic transformation to detectable phase I metabolites, and elimination via renal and fecal routes. Typical clinical tablet strengths contain low milligram doses of samidorphan co-formulated with therapeutic olanzapine doses. Analytical control strategy for the active pharmaceutical ingredient includes identification, assay, and stability testing using validated HPLC and LC-MS methods and control of specified and unspecified degradation products.
Parent: Samidorphan
Related substances and impurity classes monitored for samidorphan include synthetic precursors, process-related byproducts, stereoisomeric impurities, N-dealkylated and hydroxylated metabolites, and N-oxide derivatives. Typical quality specifications follow ICH Q3A/Q3B principles: individual specified impurities are commonly limited to not more than 0.10 to 0.30 weight percent depending on identification and toxicological assessment, total impurities are controlled to not exceed about 1.0 weight percent, and assay acceptance is typically in the high 90s percent range to ensure dose accuracy. Genotoxic impurity thresholds, when applicable, are set at low parts-per-million levels consistent with ICH M7. Residual solvents and elemental impurities are controlled to pharmacopeial limits with appropriate testing. Stability studies define impurity profiles over shelf life and provide corrective specification adjustments when justified by risk assessment and regulatory guidance.
Samidorphan, as part of an olanzapine/samidorphan combination product, is used to treat schizophrenia and bipolar disorder while reducing olanzapine-associated weight gain. Alone, samidorphan functions as an opioid receptor antagonist and is not substituted for antipsychotic therapy.
Samidorphan and naltrexone are both opioid receptor antagonists, but they differ in chemical structure, receptor selectivity, pharmacokinetic properties, and clinical development paths. Both block mu opioid receptors, yet samidorphan was specifically developed and dosed for co-administration with olanzapine to address antipsychotic-related weight effects.
The exact mechanism is not fully elucidated, but samidorphan is thought to attenuate olanzapine-induced weight gain by blocking mu opioid receptor mediated effects on reward and feeding behavior and by modulating central pathways involved in appetite and energy balance. Pharmacodynamic modulation of these pathways can reduce hedonic eating and downstream metabolic changes associated with olanzapine.
Samidorphan is added to olanzapine to address a common adverse effect of olanzapine, namely clinically significant weight gain and associated metabolic consequences, while preserving olanzapine’s antipsychotic efficacy. The combination aims to provide the therapeutic benefits of olanzapine with a reduced risk of weight-related side effects.
